SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health

HONG KONG, Nov 26, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab”, or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, was invited to attend the inaugural Asia Summit On Global Health (“ASGH”), jointly […]

Inaugural Asia Summit on Global Health successfully explores healthcare landscape

HONG KONG, Nov 25, 2021 – (ACN Newswire via SEAPRWire.com) – Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (ASGH) concluded successfully yesterday (24 November). The summit took place at the Hong Kong Convention and Exhibition […]

Inaugural Asia Summit on Global Health highlights Hong Kong’s advantages

HONG KONG, Nov 17, 2021 – (ACN Newswire via SEAPRWire.com) – Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (ASGH) will take place on 24 November at the Hong Kong Convention and Exhibition Centre (HKCEC) in […]

Regional insurtech Igloo and HD, the region’s only D2C direct-pay healthcare marketplace, announce partnership to launch insurance products on HDmall

BANGKOK, Nov 4, 2021 – (ACN Newswire via SEAPRWire.com) – Regional insurtech company Igloo has teamed up with HD to provide health-related micro-insurance products via the HDmall healthcare marketplace platform in Thailand. Muang Thai Insurance (MTI), one of Thailand’s leading non-life insurance companies, will be underwriting the health insurance products such as cancer and mobile […]

China’s New Regulation on Internet Healthcare Will Benefit Platforms like WeDoctor

HONG KONG, Oct 29, 2021 – (ACN Newswire via SEAPRWire.com) – On 27 October, China’s National Health Commission (NHC), the authority responsible for the medical industry, issued a new policy that calls for the regulation of China’s fast-growing internet healthcare industry. The policy is expected to push China’s internet healthcare industry from the period of […]

NEC Utilizes Digital Technologies to Create Healthcare and Life Science Business

TOKYO, Sep 15, 2021 – (JCN Newswire via SEAPRWire.com) – NEC Corporation (TSE: 6701) announced today an initiative to create healthcare and life science business that utilizes AI and other digital technologies as part of the “creation of future growth businesses” set forth in the 2025 Mid-term Management Plan. NEC will focus on the three […]

Mediwelcome Announces 2021 Interim Results

HONG KONG, Aug 31, 2021 – (ACN Newswire via SEAPRWire.com) – The largest provider in the Integrated Healthcare Marketing Solutions Market of cardio-cerebral-vascular diseases (CCVDs), Mediwelcome Healthcare Management & Technology Inc. (“Mediwelcome” or the “Company”, together with its subsidiaries, the “Group”) is pleased to announce the unaudited consolidated interim results for the six months ended […]

EC Healthcare Announced Quarterly Sales Volume, Successfully Expanded New Flagship Service Centre

HONG KONG, Jul 27, 2021 – (ACN Newswire via SEAPRWire.com) – EC Healthcare (the “Company”, which together with its subsidiaries is referred to as the “Group”, SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces that, to fulfill the strong demand for medical and healthcare services, on 26 July 2021, the […]

Jacobson Pharma Announces FY2021 Annual Results

HONG KONG, Jun 29, 2021 – (ACN Newswire via SEAPRWire.com) – Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Company”; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries […]

EC Healthcare Acquires Pet Industry Business, Allowing Clientele and Business Synergies, To Consolidate and Corporatize Pet Industry

HONG KONG, Jun 15, 2021 – (ACN Newswire via SEAPRWire.com) – EC Healthcare (the “Company”, which together with its subsidiaries is referred to as the “Group”, SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group enters the pet industry and will acquire 51% equity interests […]

Strategic Collaboration Memorandum between EC Healthcare and China Medical System Utilizes the Synergy of Upstream and Downstream of the Aesthetic Medical Industry, Promotes the Development of Medical Products and Talents

HONG KONG, Jun 11, 2021 – (ACN Newswire via SEAPRWire.com) – EC Healthcare (the “Company”, which together with its subsidiaries is referred to as the “Group”, SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong* and China Medical System Holdings Limited (the “CMS”, SEHK stock code: 867), jointly announce that the Group […]

Dingdang Health raises US$220 million in new financing round

BEIJING, Jun 8, 2021 – (ACN Newswire via SEAPRWire.com) – China’s leading integrated online healthcare platform Dingdang Health announced today that it has raised US$220 million in its latest financing round. This round was led by TPG Capital Asia and co-led by OrbiMed and Redview Capital. Other investors included, Valliance, Travis Global Limited (which is […]

Alvotech完成第二輪私募融資 兩輪融資總額達1億美元

HONG KONG, Mar 15, 2021 – (亞太商訊 via SEAPRWire.com) – 跨國生物製藥公司Alvotech宣佈完成3,500萬美元的第二輪私募融資。第一輪達6,500萬美元的私募融資於2020年10月完成,而兩輪融資總額合共1億美元。韓國的Shinhan、美國的Baxter Healthcare SA及德國的ATHOS(Strüngmann 家族辦公室)均有參與Alvotech的第一輪私募融資。 Alvotech欣然宣佈,第二輪私募融資獲得更多冰島本土及國際投資者的支持。 Alvotech主席Robert Wessman表示:「我們很高興完成了這次私募融資。公司正處令人振奮的發展階段,由生物仿製藥開發商演變為製造商及供應商。我們期待在市場推出首項產品。」 「我們在全球各大藥品市場中,已與當地領先的生物仿製藥企業簽定合作協議,讓我們能向全球更多病患者提供優質生物製藥。」 「我對首次投資於Alvotech的投資者,包括來自我的故鄉及公司核心經營基地 — 冰島的投資者,對我們投以信心一票感到格外欣喜。」 關於AlvotechAlvotech是一家跨國生物製藥公司,致力為全球市場開發和生產優質生物仿製藥。公司是生物科技領域的專家,透過為全球合作夥伴和病患者提供優質和具有成本優勢的產品及服務,矢志成為生物仿製藥品領域的全球領導者。公司採用全面整合的策略,強大的內部能力覆蓋整個價值鏈,有助加快生物仿製藥的開發。Alvotech的股東包括由創始人兼主席Robert Wessman先生旗下的Aztiq Pharma、來自日本的Fuji Pharma、阿布達比的YAS Holdings、韓國的Shinhan、美國的Baxter Healthcare SA、德國的ATHOS(Strüngmann家族辦公室),以及通過投資Alvogen的CVC Capital Partners及新加坡的Temasek Holdings。 Alvotech初步的在研產品包括數款單克隆抗體和融合蛋白生物仿製藥,旨在治療自身免疫、腫瘤和炎症相關疾病,改善世界各地病患者的生活質素。如欲了解詳情,請瀏覽網站 www.alvotech.com,或點擊LinkedIn、Twitter和Facebook。 媒體及投資者查詢:縱橫財經公關顧問有限公司劉若琪 電話:(852) 2864 4805 電郵:angelus.lau@sprg.com.hk趙苑盈 電話:(852) 2114 4329 電郵:beverly.chiu@sprg.com.hk梁宇彤 電話:(852) 2114 4912 電郵:carrie.leung@sprg.com.hk Copyright 2021 亞太商訊. All rights reserved. (via SEAPRWire)

GBA Healthcare Working Group Releases White Paper as First Asset in Blockchain Ethical Design Framework for Healthcare

Washington, D.C., Mar 8, 2021 – (ACN Newswire via SEAPRWire.com) – Beginning early 2020, the Government Blockchain Association (GBA) Healthcare Working Group (HWG) began undertaking the development of an ethical design framework for blockchain solutions in the healthcare industry as a service to the public. The GBA HWG is releasing the first asset in the […]

基因檢測行業的未來明珠獲資本巨頭鼎力相助 諾輝健康潛力十足

HONG KONG, Feb 8, 2021 – (亞太商訊) – 開年至今,港股市場氛圍熱烈,康希諾生物、榮昌生物、康方生物等生物科技公司漲勢喜人。由於新冠肺炎疫情仍在世界範圍擴散,促使醫療需求急劇上升,此類生物科技領域的「18A上市公司」自2020年以來愈發受到市場關注,股價表現亮眼。 近期恰有數家生物科技公司預備上市,諾輝健康正是其中之一。諾輝健康是中國癌症篩查市場的先行者,旨在大力推進癌症篩查技術創新,並加快癌症篩查技術於中國的採用。 基因檢測行業的未來明珠癌症篩查主要針對普通人群,旨在無症狀或癌前病變階段盡早發現癌症,以實現癌症的預防或治癒。在有利政策及投資的大力推動下,國內首款且唯一獲批國家藥監局癌症早篩許可證的癌症篩查測試產品,由諾輝健康自主研發的常衛清®已得到中國首部結直腸癌篩查指南和多項權威臨床共識推薦,正式開始進入商業化階段,市場前景可期。 據招股書披露,諾輝健康目前產品管線覆蓋了中國10大高發癌種的3個,分別是結直腸癌、胃癌和宮頸癌,三大市場預計到2030年均將突破百億。 結直腸癌是諾輝健康最早佈局的癌種,與美國癌症早篩標杆Exact Sciences(精密科學)不謀而合。據海通國際2021年1月28日發佈的研究報告,精密科學在過去的10年市值上漲36倍。 諾輝健康旗下的兩款結直腸癌篩查產品(常衛清®和噗噗管®)有效互補並全面覆蓋了中國抗癌協會推薦定期接受結直腸癌篩查的目標人群。兩款產品均已獲得國家藥品監督管理局的批准並正式開始商業化。噗噗管為中國首個且唯一一個獲國家藥監局批准的自檢FIT篩查產品。 針對中國發病率第二高的胃癌,諾輝健康正在開發的幽幽管產品是基於糞便的自檢胃癌篩查測試,已於2020年11月完成註冊試驗,並已同時向國家藥監局提交註冊申請。 諾輝健康的在研管線還包括宮證清,一種非侵入性宮頸癌家用篩查測試,通過檢測尿液即可實現宮頸癌篩查,預計將最早於2021年最後一季度前啟動宮證清註冊試驗。中國目前沒有家用型尿液宮頸癌篩查測試產品。 通過全國的醫院、體檢中心、藥店及網上等多個管道,諾輝健康不斷營銷其現有產品,持續激發癌症篩查市場的潛力,提升產品的商業價值。 投資機構的新興焦點截至目前,諾輝健康多次獲得全球知名風險投資、頂級生物醫療基金和長線投資機構的持續關注,投資總金額逾1.6億美元,是癌症篩查領域迄今最受投資人青睞的公司。據公開資料,諾輝健康牽手君聯資本、啟明創投、奧博資本、軟銀中國資本以及Rock Springs等資本巨頭。尤其值得關注的是,諾輝健康E輪領投方Rock Springs也是美國癌症早篩標杆Exact Sciences(精密科學)的投資方。 此次,諾輝健康引入了16名基石投資者,包括景順、清池資本、博裕資本、GIC、加皇環球資產管理、Columbia Funds、Janus Henderson Funds、Rock Springs Capital、Worldwide Healthcare Trust PLC、LAV、Cormorant Global、HBC Asia Healthcare Opportunities VII LLC、Octagon Investments、Sage Partners、南方基金管理有限公司及E Fund,合共認購1.24億美元股份。 癌症早篩行業具有獨特的技術壁壘和臨床壁壘,常衛清作為癌症早篩早篩領域的「中國第一證」具備獨特的先行者優勢,利於產生規模效應並擴大成本優勢,外加擁有豐富成功經驗及遠見的管理團隊攜手頂級醫療健康領域投資者,諾輝健康未來的潛力不可限量。 Copyright 2021 亞太商訊. All rights reserved. www.acnnewswire.com

諾輝健康商業前景可觀 長期投資價值極佳

HONG KONG, Feb 5, 2021 – (亞太商訊) – 香港特區政府2018年正式啟動的大腸癌篩查先導計劃現已進入第三階段。此計劃旨在為50至75歲沒有大腸癌症狀的香港居民提供篩查資助,以預防大腸癌。據香港衛生署署長陳漢儀介紹,在2011年及2013年,大腸癌已超越肺癌成為全香港最常見的癌症。 癌症篩查對於預防癌症,提高早診率、治療率,降低發病率和死亡率有著重大作用。科學研究表明:定期的腸鏡檢查能夠使結直腸癌發病率和死亡率降低40%—60%。因此,癌症早篩技術,被權威學術期刊《自然醫學》列入2020年令人矚目的10項醫學領域的進步之一。 產品優良 諾輝健康前景光明 目前來看,癌症早篩公司的發展前景均十分可觀。例如,美國癌症早篩標杆企業Exact Sciences(精密科學)的市值在10年內上漲36倍。精密科學的投資方Rock Springs也是中國癌症早篩公司——諾輝健康E輪融資的領投方。癌症早篩賽道寬闊,諾輝健康發展成為中國的精密科學並非沒有可能。 諾輝健康的核心產品常衛清已拿下中國癌症早篩第一證,這是首個也是唯一一個獲得國家藥監局批准的癌症早篩測試。而其跟隨者尚處於研發早期,若要追趕諾輝健康,至少需要4-5年的時間。諾輝健康已成為中國癌症早篩標桿企業,與同行相比,擁有巨大的先發優勢。 技術水平決定產品高度。截至最後實際可行日期,諾輝健康於全球建立包含71項專利及專利申請的組合,確立了對于同行的技術領先優勢。從效果來看,常衛清的性能已經是全球最佳,跟隨者至多能夠證明自身臨床數據優劣,但並不能超越諾輝健康現有成果。臨床數據表明,常衛清對結直腸癌及進展期腺瘤的靈敏度分別達95.5%及63.5%,整體特異性為87.1%,而對結直腸癌的NPV為99.6%,可以最大程度防止漏检,保護受測者的利益,對結直腸癌及進展期腺瘤的PPV則合共為46.2%。根據弗若斯特沙利文的報告,常衛清是中國目前唯一能夠檢測出癌前病變(如進展期腺瘤)的癌症篩查測試。 此外,諾輝健康已對亞洲特定結直腸癌甲基化譜建立專有的龐大數據庫,收集臨床糞便樣本超過100,000個。因此,諾輝健康的產品對亞洲人更具有針對性和適用性,其發展前景值得期待。 商業化進程開啟 盈利能力持續增強 諾輝健康旗下的常衛清及噗噗管形成互補,已正式启动商業化進程。常衛清面向1.20億結直腸癌高风险人群(2019年數據),具有較高的靈敏度。噗噗管面向结直肠癌平均风险的大眾市場,2019年潛在用戶6.33億人,居家自测方便,是中國首個且唯一居家自檢的便隱血(FIT)檢測產品,已獲得國家藥品監督管理局審批並取得歐盟CE認證。 近年來,諾輝健康收入不斷增長,盈利能力日漸增強。2019年,諾輝健康實現收入5827.5萬元,較2018年的1881.6萬元大增209.71%。主要受疫情影響,2020年前九個月,諾輝健康收入為3530.9萬元,與2019年同期3544.0基本持平。2020年10月份以來,諾輝健康常衛清的出貨量大幅增長,2020年第三季度同比增加17.6%,其中10月份同比大增46.4%。 目前來看,諾輝健康商業化佈局已經較為完善,主要管道全面覆蓋,臨床、體檢以及保險、直營電商等多點齊發。後期隨著市場滲透率提升及產品放量,將會形成較強的規模經濟效用,銷售費用和成本都有望降低,形成新的競爭優勢。 此次上市,公司還得到了Invesco、Lake Bleu、Boyu Capital、GIC、加皇環球資產管理(亞洲)、Columbia Funds、Janus Henderson、Rock Springs Capital、Worldwide Healthcare Trust PLC、LAV、Cormorant Global、HBC Asia Healthcare Opportunities VII LLC、Octagon Capital Advisors、Sage Partners Master Fund、南方基金和E Fund等16名基石投資者的大力支持。預期將於2月5日正式招股。隨著公司商業化進程加速,諾輝健康將在前景廣闊的中國市場獨領風騷,帶給投資者極佳的長期回報。 Copyright 2021 亞太商訊. All rights reserved. www.acnnewswire.com